Results 71 to 80 of about 900,797 (391)

Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib

Clinical Pharmacokinetics, 2019
Nintedanib is an oral, small-molecule tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary fibrosis and patients with advanced non-small cell cancer of adenocarcinoma tumour histology.
S. Wind, U. Schmid, M. Freiwald, K. Marzin, Ralf R. H. Lotz, T. Ebner, P. Stopfer, Claudia Dallinger   +7 more
semanticscholar   +1 more source

Olaparib synergy screen reveals Exemestane induces replication stress in triple‐negative breast cancer

Molecular Oncology, EarlyView.
Screening 166 FDA‐approved anticancer drugs identifies the aromatase inhibitor Exemestane as a synergistic partner of PARP inhibitor Olaparib in BRCA‐proficient triple‐negative breast cancer. Exemestane induces ROS‐mediated replication stress, enhancing DNA damage and apoptosis alongside Olaparib.
Nur Aininie Yusoh, Liping Su, Suet Lin Chia, Xiaohe Tian, Haslina Ahmad, Martin R. Gill   +5 more
wiley   +1 more source

Bioequivalence trials for the approval of generic drugs in Saudi Arabia: a descriptive analysis of design aspects

BMC Medical Research Methodology
Background This retrospective analysis aimed to comprehensively review the design and regulatory aspects of bioequivalence trials submitted to the Saudi Food and Drug Authority (SFDA) since 2017.
Turki A. Althunian, Bader R. Alzenaidy, Raseel A. Alroba, Ohoud A. Almadani, Fahad A. Alqahtani, Albatool A. Binajlan, Amal I. Almousa, Deema K. Alamr, Malak S. Al-Mofada, Nora Y. Alsaqer, Hessa A. Alarfaj, Abdulmohsen A. Bahlewa, Mohammed A. Alharbi, Ali M. Alhomaidan, Abdulaziz A. Alsuwyeh, Abdulmohsen A. Alsaleh   +15 more
doaj   +1 more source

Predictors of response and rational combinations for the novel MCL‐1 inhibitor MIK665 in acute myeloid leukemia

Molecular Oncology, EarlyView.
This study characterizes the responses of primary acute myeloid leukemia (AML) patient samples to the MCL‐1 inhibitor MIK665. The results revealed that monocytic differentiation is associated with MIK665 sensitivity. Conversely, elevated ABCB1 expression is a potential biomarker of resistance to the treatment, which can be overcome by the combination ...
Joseph Saad, Rhiannon Newman, Elmira Khabusheva, Sofia Aakko, Eric Durand, Mahesh Tambe, Heikki Kuusanmäki, Alun Parsons, Juho J. Miettinen, Komal Kumar Javarappa, Ezgi June Olgac, Nemo Ikonen, Mika Kontro, Kimmo Porkka, Heiko Maacke, Janghee Woo, Ensar Halilovic, Caroline A. Heckman   +17 more
wiley   +1 more source

Physiologically based pharmacokinetic modeling for development and applications of a virtual celiac disease population using felodipine as a model drug

CPT: Pharmacometrics & Systems Pharmacology, 2023
In celiac disease (CeD), gastrointestinal CYP3A4 abundance and morphology is affected by the severity of disease. Therefore, exposure to CYP3A4 substrates and extent of drug interactions is altered.
Farzaneh Salem, Ali Nimavardi, Jennypher Mudunuru, Debra Tompson, Jackie Bloomer, David B. Turner, Kunal S. Taskar   +6 more
doaj   +1 more source

Pharmacokinetics and tumor dynamics of the nanoparticle IT-101 from PET imaging and tumor histological measurements [PDF]

, 2009
IT-101, a cyclodextrin polymer-based nanoparticle containing camptothecin, is in clinical development for the treatment of cancer. Multiorgan pharmacokinetics and accumulation in tumor tissue of IT-101 is investigated by using PET.
Alley, B. C. Mack, Braet, C. A. Alabi, C. H. J. Choi, Carter, Cheng, Cheng, Davis, Davis, Dreher, Drummond, Hashizume, Heidel, Hobbs, I. J. Hildebrandt, J. Czernin, J. Hwang, Kirpotin, Loening, M. E. Davis, Matsumura, Moore, O'Connor, Reddy, Riches, Schluep, Schluep, Schluep, T. Schluep, Tabata, Tirona, Torchilin, Yuan   +33 more
core   +3 more sources

Report on the 2nd MObility for Vesicle research in Europe (MOVE) symposium—2024

FEBS Open Bio, EarlyView.
The 2nd MObility for Vesicle research in Europe (MOVE) Symposium in Belgrade brought over 280 attendees from 28 countries to advance extracellular vesicle (EV) research. Featuring keynotes, presentations, and industry sessions, it covered EV biogenesis, biomarkers, therapies, and manufacturing.
Dorival Mendes Rodrigues‐Junior, Michaela Kocholata, Marilena E. Lekka, Olga Janouskova, Moran Yadid, Maja Kosanovic   +5 more
wiley   +1 more source

The pharmacokinetics of voriconazole [PDF]

British Journal of Clinical Pharmacology, 2003
Voriconazole (Vfend® Pfizer Global Research and Development, Sandwich, Kent, UK) is a broad-spectrum antifungal triazole that is structurally related to fluconazole. As with all triazole antifungal agents, voriconazole works principally by inhibition of cytochrome P450 14-α-demethylase (P450 14DM) [1, 2].
openaire   +3 more sources

Research progress on the metabolic transformation of Shenling Baizhu San under the influence of the gut microbiota

Advanced Chinese Medicine, EarlyView.
Abstract The gut microbiota plays a pivotal role in maintaining host metabolic homeostasis and overall physiological functions. Shenling Baizhu San (SLBZS), a time‐honored classical prescription for tonifying Qi, strengthening the spleen, removing dampness, and arresting diarrhea, has shown broad clinical efficacy in digestive disorders.
Jinlan Di, Xiaochun Zhang
wiley   +1 more source

Pharmacokinetic modeling of over-the-counter drug diphenhydramine self-administered in overdoses in Japanese patients admitted to hospital

Journal of Pharmaceutical Health Care and Sciences, 2021
Background Although the over-the-counter H1 receptor antagonist diphenhydramine is not a common drug of abuse, it was recently recognized as one of the substances causing acute poisoning in patients attempting suicide that led to admissions to our ...
Koichiro Adachi, Satoru Beppu, Mariko Terashima, Wataru Kobari, Makiko Shimizu, Hiroshi Yamazaki   +5 more
doaj   +1 more source